Veeva Systems Strengthens Global Pharmacovigilance through Partnership with UCB and Safety Suite Implementation

Veeva Systems (VEEV) facilitates a significant advancement in global pharmacovigilance through its strategic partnership with UCB, announced on June 9, 2026.

Revolutionizing Safety Operations with Veeva Safety Suite

This collaboration centers on the deployment of the Veeva Safety Suite, a comprehensive platform designed to unify and enhance safety operations across UCB's global network. By adopting this integrated solution, UCB aims to maximize operational efficiency and ensure standardized safety data management. The implementation of the Veeva Safety Suite sets the stage for UCB to accelerate the processing of adverse events, streamline submissions to regulatory authorities, and improve oversight through a single source of truth for safety information. This strategic move marks a pivotal step in UCB's safety transformation, with Jonas Maselis, head of digital technology for patient safety at UCB, highlighting the necessity of this transition to enhance workflows and data reliability.

The Veeva Safety Suite encompasses several critical components aimed at fortifying UCB's pharmacovigilance capabilities. Veeva Safety allows efficient processing of adverse event reports, while Veeva SafetyDocs facilitates the management of safety-related content. Furthermore, the Veeva Safety Workbench leverages advanced data analysis tools that provide actionable insights into safety data. Enhanced automation features, such as Veeva Safety Signal for automated signal detection, significantly improve organizational visibility and coordination. These elements work cohesively to optimize UCB’s global safety operations, ultimately aiming to ensure compliance and uphold the highest standards in patient safety.

Commitment to Innovation in Life Sciences

John Lawrie, vice president of Veeva Safety, emphasizes that the unified framework provided by the Veeva Safety Suite not only enhances regulatory compliance but also elevates automation capabilities within UCB's pharmacovigilance functions. This partnership underlines Veeva Systems' commitment to delivering innovative solutions within the life sciences sector, as the company continues to serve over 1,500 clients, ranging from leading pharmaceutical firms to pioneering biotech companies. The collaboration with UCB is a testament to Veeva's ongoing mission to optimize safety management processes and improve the delivery of safe and effective medicines to patients worldwide.

Standardizing Processes for Enhanced Patient Safety

In addition to enhancing operational efficiencies, this partnership underscores UCB’s strategic goal of standardizing safety processes across multiple regions. By leveraging Veeva’s powerful suite, UCB can improve transparency and streamline pharmacovigilance efforts, thus enhancing patient safety outcomes on a global scale. As both companies move forward, the emphasis on automation and routine standardization is expected to play a critical role in shaping the future of safety operations in the life sciences industry.